ESMO 2024: Highlights and analysis
Although we can be optimistic thanks to the great advances that have been made in the field, there are still unacceptable levels of variation, with high cancer rates found in certain countries and socio-economic groups and a disparity in between the opinions of patients and doctors of what should be considered successful treatment.
Among the numerous studies on pregnancy and fertility, a number of key points arose, including: the low level of understanding among young women of how treatments can affect fertility; research indicating that treating pregnant women with chemotherapy poses a relatively low risk to the unborn child; a study showing that women who had been treated with chemotherapy did not have a reduced chance of becoming pregnant in the future.
The issue of communication has also come to light. A panel discussion identified a lack of clarity in the information provided outlining the risk of contracting cancer when a mutated BRC-1 or BRC-2 gene is identified.
ESMO 2024: Highlights and analysis
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Antibody drug conjugates coming to primetime and new agents for breast cancer
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer
Comment: EBCC 2024 highlights